Olive Oil, GLP-1 and Appetite: What the Mechanism Really Shows

A claim now circulating says olive oil "pulls the same levers as Ozempic." The surprise is how much of the pharmacology behind it is real. Digesting olive oil genuinely produces 2-oleoylglycerol, which genuinely activates GPR119 on the hormone-secreting L-cells of the gut, which genuinely releases GLP-1 — the hormone semaglutide was engineered to imitate. Oleic acid genuinely becomes oleoylethanolamide, which acts on PPAR-alpha to raise fat oxidation and lower food intake. None of that is invented. The equivalence is. Endogenous GLP-1 has a half-life of roughly one to two minutes; semaglutide's is about a week — and this exact pathway has already been tested twice as a drug target, with results nobody quotes. This page walks the mechanism, checks the arithmetic the claims rest on, and supplies the caveat the source omits entirely: olive oil is about 120 calories a tablespoon, and nearly every trial showing benefit gave it as a replacement for other fat, not as an addition on top.

Table of Contents

  1. GLP-1: The Hormone Your Gut Already Makes
  2. 2-Oleoylglycerol and the GPR119 Switch
  3. Does 5 mL of Olive Oil Really Make 2 Grams of 2-OG?
  4. The Copenhagen Carrot Trial
  5. Oleoylethanolamide and PPAR-alpha
  6. Why a Knockout Beats a Correlation
  7. CCK, PYY and Slower Gastric Emptying
  8. Olive Oil Is Not Ozempic: Where the Comparison Breaks
  9. This Pathway Was Already Tested as a Drug — Twice
  10. 120 Calories a Tablespoon: Addition Versus Substitution
  11. "Fat Loss 80% Higher" — Relative Versus Absolute
  12. The EFSA Polyphenol Threshold
  13. Who Is Telling You This, and What Is Being Sold
  14. What a Trial That Settled This Would Look Like
  15. Evidence Ledger
  16. What Is Actually Reasonable to Do
  17. Key Research Papers
  18. Connections

GLP-1: The Hormone Your Gut Already Makes

Glucagon-like peptide-1 (GLP-1) is cut from the precursor proglucagon by enteroendocrine L-cells in the intestinal lining and released when nutrients arrive in the lumen. It amplifies insulin release from the pancreatic beta cell, but only when glucose is already elevated — the "incretin effect," which is why GLP-1 signalling does not by itself cause hypoglycaemia. It also suppresses glucagon, slows gastric emptying, and signals satiety to the brain via the vagus nerve.

That you already make GLP-1 is entirely true and no secret. It is textbook physiology and the reason the drug class exists. What matters is the fact the video omits.

Native GLP-1 has a plasma half-life of roughly one to two minutes. Dipeptidyl peptidase-4 (DPP-4) clips two amino acids off the N-terminus and inactivates the hormone almost as fast as it is secreted; much is degraded before it leaves the gut circulation. That is why native GLP-1 was never viable as a drug — it would need continuous infusion. Everything a meal does to GLP-1 is therefore transient by construction, and that is the hinge of the Ozempic comparison. See the site's page on GLP-1 receptor agonists.

Back to Table of Contents

2-Oleoylglycerol and the GPR119 Switch

Dietary fat arrives as triacylglycerol: glycerol with three fatty acids at positions sn-1, sn-2 and sn-3. Pancreatic lipase is sn-1,3-specific — it cleaves the two outer fatty acids and leaves the middle one attached, so complete lipolysis yields two free fatty acids and one 2-monoacylglycerol.

Which one depends on what sits at sn-2. In olive oil that position is strongly enriched in oleic acid — the oil is roughly 55–83% oleic by total fatty acid, and sn-2 is more oleic-rich still. So olive oil yields predominantly 2-oleoylglycerol (2-OG), an agonist at GPR119, a receptor on L-cells, K-cells and pancreatic beta cells whose activation raises cyclic AMP and triggers GLP-1 secretion. The chain: olive oil → lipase cleaves sn-1 and sn-3 → 2-oleoylglycerol → GPR119 on L-cells → cyclic AMP → GLP-1 release → slowed gastric emptying, amplified insulin, satiety — for the minute or two the hormone survives.

Two details are usually skipped. L-cell density is not uniform: L-cells grow more abundant moving distally and are densest in ileum and colon, while fat digestion products are absorbed mostly in duodenum and jejunum. The classic puzzle — how a meal raises GLP-1 within 15 minutes, long before food could travel that far — resolves through proximal L-cells that do exist in duodenum and jejunum, plus a neural and humoral loop that primes distal cells in advance. Neither undermines the finding; both explain why the response is real but modest.

Second, oleoylethanolamide is itself a GPR119 agonist. The two arms the video presents as separate converge on the same receptor, with oleoylethanolamide additionally acting at a nuclear receptor — a unification the source misses.

Back to Table of Contents

Does 5 mL of Olive Oil Really Make 2 Grams of 2-OG?

The video claims that digesting 5 mL of olive oil — one teaspoon — produces roughly 2 g of 2-OG. That is a number to check, not repeat. Every assumption is printed here.

  1. Mass. Olive oil density is about 0.916 g/mL. 5 mL × 0.916 = 4.58 g.
  2. Starting molecular weight. Treating the oil as triolein, its most abundant triacylglycerol species: 885.4 g/mol.
  3. Moles. 4.58 ÷ 885.4 = 5.17 mmol.
  4. Stoichiometry. sn-1,3-specific lipase yields exactly one 2-monoacylglycerol per triacylglycerol → 5.17 mmol of 2-OG.
  5. Product molecular weight. 2-monoolein: 356.5 g/mol.
  6. Mass of 2-OG. 5.17 mmol × 356.5 mg/mmol = 1.84 g.

A mass-fraction check agrees: 356.5 ÷ 885.4 = 40.3%, and 40.3% of 4.58 g is 1.85 g. The arithmetic holds — 1.8 g against a claimed "roughly 2 g" is within eight percent. Worth saying plainly, because many numbers in this genre do not survive the treatment.

But it is a theoretical ceiling, not a delivered dose. It assumes complete hydrolysis with no onward breakdown, when 2-monoacylglycerol isomerises to 1-monoacylglycerol that lipase can then cleave. It assumes every triacylglycerol is triolein, when olive oil also carries palmitic, linoleic and stearic acid in mixed species of differing weights. Most decisively, it is a mass in transit, not a concentration at a receptor: 2-OG is absorbed by enterocytes and re-esterified into chylomicrons within minutes, so 1.84 g is the total passing through the lumen across the whole of digestion, and only the fraction meeting an L-cell in intact form can signal.

So the chemistry is right and the framing is misleading. "One teaspoon makes two grams of the molecule that flips the switch" invites you to picture two grams of drug hitting a receptor. What it describes is that roughly forty percent of any fat you eat transits the gut as a monoacylglycerol — equally true of butter, lard and sunflower oil. What is specific to olive oil is the identity of the fatty acid at sn-2, not the quantity of monoacylglycerol.

Back to Table of Contents

The Copenhagen Carrot Trial

The human anchor is a crossover feeding study conducted in Copenhagen and reported by Mandøe and colleagues in the American Journal of Clinical Nutrition around 2015: randomised, single-blind, crossover, in 12 healthy men, with four test meals on four days — 200 g of carrots alone, carrots plus a short-chain fat, carrots plus a medium-chain fat, and carrots plus roughly 19 g of olive oil. GLP-1, peptide YY, neurotensin and cholecystokinin were measured, and the reported conclusion was that the 2-monoacylglycerol formed on digestion accounts for the olive-oil-induced release. Exact volume, issue and page metadata are not asserted here; the design above comes from a secondary source and should be checked against the paper using the topic search below.

What is genuinely strong about it. Run through the usual checks for borrowed evidence, it comes back unusually clean: right species (human), right route (oral, with food), right preparation (ordinary olive oil drizzled on a vegetable — not an extract or capsule — which is exactly the use recommended), and a real comparator, since short- and medium-chain fatty acids are largely absorbed without the same lipase-and-2-monoacylglycerol route. If the effect tracked "fat" in general it should have appeared in those arms too. That combination is rare in this genre, and it is why the mechanism sections above are written in the indicative rather than the conditional.

What it does not show — the boundaries of one postprandial study, not criticisms of the researchers:

  1. The endpoint is a hormone concentration, not an outcome. Nobody was weighed. Treating a postprandial GLP-1 curve as a fat-loss result is endpoint substitution, the largest logical leap in the video.
  2. Twelve healthy young men is a mechanism sample, not a population. It says nothing about women, older adults, or people with obesity or type 2 diabetes — and that last group matters most, because the endogenous GLP-1 response is blunted in exactly those people. The mechanism may be weakest where it is most wanted.
  3. A drizzle cannot be blinded. You can see and taste 19 g of oil on carrots. Irrelevant for hormone assays; decisive for anything appetite-related.
  4. One meal, no follow-up. Whether the response persists, attenuates or is compensated for over weeks was not asked.

One correction. The video says the plain carrot meal "did not" trigger GLP-1 release. That is not plausible: carbohydrate is itself a potent GLP-1 secretagogue — luminal glucose stimulates L-cells through the cotransporter SGLT1 — and 200 g of carrots is a carbohydrate load. What such a trial shows is that the olive-oil meal produced a substantially larger response. A difference in magnitude is the honest claim, and still an interesting one.

Back to Table of Contents

Oleoylethanolamide and PPAR-alpha

The second mechanism is separate from GLP-1 and, if anything, better established. Oleic acid absorbed by enterocytes is conjugated with ethanolamine to form oleoylethanolamide (OEA) — also spelled oleylethanolamide in much of the primary literature, worth knowing before searching for it.

OEA is not a classical hormone but a lipid messenger, chemically kin to the endocannabinoid anandamide but behaviourally opposite: anandamide drives feeding, OEA suppresses it. It is made locally in the gut in proportion to the meal's oleic-acid content and degraded locally too, so its action is regional rather than systemic.

Its principal target is PPAR-alpha, a nuclear receptor and transcription factor that is the master regulator of the fasting fat-oxidation programme — activation upregulates genes for fatty-acid uptake, mitochondrial beta-oxidation and ketogenesis. It is the same receptor the fibrate lipid drugs target. The satiety signal is transmitted to the brain rather than exerted in it, travelling by vagal afferent fibres to the brainstem and on to hypothalamic feeding circuits; severing the vagus abolishes it. That is why OEA reduces meal size rather than acting as a general appetite suppressant.

The site's Olive Oil overview and the avocado pages on monounsaturated fats and fibre and satiety describe the same pathway from the other direction — itself a corrective, because it means this is a property of high-oleic fat, not of olive oil specifically. Avocado, high-oleic sunflower oil and even beef fat deliver oleic acid at sn-2.

Back to Table of Contents

Why a Knockout Beats a Correlation

The OEA-to-PPAR-alpha link rests on a knockout experiment reported by Fu and colleagues in Nature around 2003, and the video is right to single it out. Why a knockout is a different tier of evidence generalises far beyond olive oil.

An observational finding — people who eat more olive oil are leaner — is compatible with explanations having nothing to do with olive oil: wealth, vegetable intake, smoking, walkable neighbourhoods. A postprandial hormone rise is better, because the timing is right and the comparison is within-subject, but it still only shows two things moving together. A receptor knockout tests causation directly: if OEA reduces feeding through PPAR-alpha, an animal lacking PPAR-alpha should be immune to it. Give the same dose to a normal mouse and to a PPAR-alpha-null mouse; if the effect vanishes in the null animal, the receptor is not merely associated with the effect, it is required for it. No confounder survives that design, because the only variable is the presence of the receptor.

Now the correction, because the video overstates it substantially. Its summary is: "no receptor and nothing happened. Zero lipolysis, zero fat burning." That is not what a PPAR-alpha knockout shows, nor what PPAR-alpha does.

The difference matters because "zero fat burning without this receptor" implies olive oil switches on something without which you cannot lose fat at all. It does not; it nudges one input into a system with large, independent and far more powerful controls.

Two further cautions. The video narrates one study that exposed fat cells to OEA, repeated it in muscle, liver and heart, then ran the knockout — a composite of at least two separate lines of work, the Nature feeding study and separate cell experiments on lipolysis, which should not be merged. The adipocyte result is not identified precisely enough here to cite, so a topic search is given rather than a fabricated attribution. And the whole OEA arm is rodent work: the knockout is a mouse. The human end is thin — one study, described by the video as appearing in Food & Function in 2015, in which a meal's oleic-acid content drove the OEA response and that response predicted reduced intake at the next meal; that metadata is unverified and reported as the video reports it. Rodent mechanism plus one human meal study supports "plausible and probably real," not a weight-loss protocol.

Back to Table of Contents

CCK, PYY and Slower Gastric Emptying

The least glamorous part of the story is probably the most reliable, and it is the honest reason a fatty meal feels more filling than a fat-free one.

Cholecystokinin (CCK) is released by I-cells of the duodenum and jejunum in response to fat and protein digestion products. It contracts the gallbladder to release bile, stimulates pancreatic enzyme secretion, slows gastric emptying, and signals satiety via vagal afferents — one of the oldest and best-characterised satiety signals in physiology, described decades before GLP-1 became fashionable. Peptide YY is co-secreted with GLP-1 from the same L-cells and drives the "ileal brake," slowing transit when nutrients reach the distal small intestine. Slowed gastric emptying is the common consequence and the most direct explanation for fullness, and it requires none of the receptor pharmacology above — fat has been known to delay gastric emptying for a very long time.

The video is right that this is also one of the main things GLP-1 drugs do. Three additions:

Back to Table of Contents

Olive Oil Is Not Ozempic: Where the Comparison Breaks

The claim is that olive oil pulls "not a similar lever — the same one." At the level of the receptor that is defensible: both ultimately act at the GLP-1 receptor. Everything downstream is not.

Duration and receptor occupancy

Semaglutide is not GLP-1. It is a GLP-1 receptor agonist: a peptide analogue engineered to resist DPP-4 cleavage and to bind albumin, which keeps it in circulation. Its half-life is approximately one week, which is why it is dosed weekly; native GLP-1's is one to two minutes. One week (10,080 minutes) against 1.5 minutes is a ratio near 6,700-fold. Those are round assumptions, but no reasonable inputs bring the two within three orders of magnitude. That is the difference between a signal and a state.

Without contested numbers: a meal raises GLP-1 beginning within about 15 minutes, peaking within an hour, returning toward baseline within two or three hours. Three meals might hold the receptor above baseline four to six hours out of twenty-four, modestly, with DPP-4 eroding it throughout. Semaglutide at steady state occupies the receptor continuously, all day, for the duration of therapy — no trough, no meal-dependence. The pharmacological question was never "can we raise GLP-1 signalling?" (food does that) but "can we raise it and never let it fall?" That is the innovation, and the one thing a drizzle cannot do by definition.

A caution on molar comparisons: semaglutide is more than 99% albumin-bound, so total plasma drug substantially overstates the free fraction available to receptors. Anyone quoting a thousand-fold concentration ratio is quoting a number needing that correction. The duration argument does not, which is why it is the one to rely on.

Effect size, and a longer pathway

Semaglutide's weight-loss trials report mean body-weight reductions in the region of fifteen percent over roughly a year and a half, against placebo arms losing low single digits. Figures, trial names and the less-advertised parts — lean-mass loss, gastrointestinal side effects, roughly two-thirds regain within a year of stopping — are on the site's page on GLP-1 receptor agonists. No trial of olive oil reports anything in that class, and none claims to; the largest reported body-composition effects are on the order of a kilogram or two, in trials where it replaced other fats.

Semaglutide also binds the receptor directly. Olive oil must be emulsified, hydrolysed at a rate set by the rest of the meal, yield 2-OG that survives isomerisation, meet GPR119 before absorption, trigger secretion from an L-cell population whose responsiveness is blunted in obesity and type 2 diabetes, and produce a hormone DPP-4 begins destroying immediately. Every step attenuates the signal.

The honest framing: olive oil nudges a pathway the drug saturates. Both halves are true and neither cancels the other. The mechanism is real, the receptor is the same, the food does something measurable — and it is not a substitute for a drug, does not produce comparable outcomes, and should never be offered to someone taking or considering GLP-1 therapy as an alternative to it. Those decisions belong with a prescriber.

Back to Table of Contents

This Pathway Was Already Tested as a Drug — Twice

The strongest test of a mechanistic hypothesis is not another mechanism study. It is finding out whether anyone already pointed a drug at that exact target. Two such tests exist here, and neither is quoted by anyone promoting the olive-oil version.

GPR119 agonists

GPR119 was attractive for exactly the reason the video finds it exciting: activating it should release GLP-1 and GIP from the gut and stimulate insulin glucose-dependently. Multiple pharmaceutical programmes pursued synthetic GPR119 agonists for type 2 diabetes through the 2000s and 2010s, and several reached early clinical trials.

There is no approved GPR119 agonist, for any indication, in any jurisdiction. That statement is unambiguous and checkable. The reasons reported in the literature — incretin and glycaemic effects that were modest and attenuated with continued dosing, consistent with receptor desensitisation — are given as reported rather than asserted, with a topic search below. What it establishes: flipping GPR119 with a purpose-built, orally dosed, pharmacologically optimised molecule, at a dose no food can deliver, did not produce a clinically compelling result. A teaspoon of olive oil flips the same switch, less hard and less often.

DPP-4 inhibitors — the cleanest benchmark available

This tests the exact proposition "raise your own GLP-1 rather than injecting an analogue." The gliptins — sitagliptin, linagliptin, saxagliptin, alogliptin — inhibit DPP-4, the enzyme that destroys native GLP-1. They add no hormone; they stop the degradation, roughly doubling active endogenous GLP-1 and holding it there all day, every day, for as long as the drug is taken. This is the maximal, pharmaceutical-grade version of "boost your own GLP-1."

Their documented effects: HbA1c reduction of roughly 0.5 to 0.8 percentage points, good tolerability, low hypoglycaemia risk — and they are weight-neutral. That characterisation appears in essentially every diabetes treatment guideline, and it is why the gliptins were displaced by GLP-1 receptor agonists once weight became the endpoint people cared about. Read against the olive-oil claim: doubling endogenous GLP-1 pharmacologically and continuously, for years, does not produce weight loss. A meal-triggered, minutes-long, partial elevation is a considerably weaker intervention.

Two fair qualifications, since the argument is strong enough to deserve its weaknesses attached. DPP-4 has substrates besides GLP-1 — notably GIP, whose metabolic effects differ — so gliptin pharmacology is not a pure GLP-1 experiment; and the weight-neutrality data come mostly from people with type 2 diabetes, in whom incretin responses are already blunted. Neither changes the direction of the conclusion.

What the pair implies is not that olive oil is useless — the pages on heart health and polyphenols and oleocanthal document well-supported effects. It implies that the GLP-1 arm is unlikely to be where olive oil's benefits come from, and that a weight-loss protocol built on that arm rests on the weakest part of the evidence.

Back to Table of Contents

120 Calories a Tablespoon: Addition Versus Substitution

The video recommends one to two tablespoons of extra-virgin olive oil on almost every meal and never mentions what that costs in energy. This is the most significant omission in the source.

Fat supplies about 9 kcal per gram and olive oil is essentially pure fat. One tablespoon is 15 mL, about 13.7 g at 0.916 g/mL, giving roughly 120 kcal per tablespoon. Three meals at 1 tbsp each is about 360 kcal/day; at 2 tbsp each, about 720 kcal/day; at a midpoint of 1.5 tbsp per meal, about 535 kcal/day — for many adults a quarter of total intake. As an upper bound if purely additive, 535 kcal/day is about 3,745 kcal a week, and the traditional rule of 3,500 kcal per pound of body fat projects roughly a pound a week. That projection is deliberately generous to the criticism and must be labelled so: the 3,500-kcal rule systematically overstates long-run weight change, because expenditure rises with body mass and the system moves toward a new equilibrium rather than gaining linearly forever. Treat it as a ceiling on the arithmetic, not a forecast.

The counter-argument, which is fair to the video. Intake is not a closed accounting system. If the fat is satiating — and the whole first half of this page argues that it is — some of those calories will be compensated for by eating less elsewhere. So the real question is not "does olive oil have calories" but how complete is the compensation at four to six tablespoons a day? Partial compensation means a net surplus; complete compensation means the drizzle is free; over-compensation would make it a weight-loss intervention. Nobody has measured this at that dose. The postprandial studies used 19 g in a single meal and measured hormones, not subsequent intake over days.

The substitution distinction

Almost every trial reporting favourable body-composition effects from olive oil is a substitution trial: participants replaced butter, margarine, seed oil or another fat with olive oil at broadly matched energy. Such a trial answers given that you are going to eat some fat, is olive oil a better fat to eat? — and the evidence that it is, is reasonably good. What none answers is what happens if you add four to six tablespoons a day on top of what you already eat?

The clearest illustration is the video's own citation: a 2017 meta-analysis of randomised trials in which olive oil was associated with reductions in body weight, BMI and waist circumference compared with other dietary fats. That comparator is the entire finding — it is the definition of a substitution design. The meta-analysis is being used to support an addition protocol, and it does not support one. The same applies to PREDIMED, covered on the heart health page: a cardiovascular-endpoint trial, not a weight-loss trial, with arms that were not energy-restricted, small weight changes, and oil consumed within a Mediterranean pattern that displaced other fats.

Stated plainly: the studies tested a swap; the protocol proposes an addition. A reader who swaps — uses olive oil instead of the fat already in the meal — is doing what the evidence supports. A reader who drizzles on top of everything is running an experiment nobody has run. See also energy density and the science of satiety; olive oil sits close to the theoretical maximum of energy density for a food.

Back to Table of Contents

"Fat Loss 80% Higher" — Relative Versus Absolute

The video cites a randomised, double-blind, placebo-controlled trial in women with excess body fat comparing extra-virgin olive oil against a control, in which fat loss was "around 80% higher in the olive oil group," alongside a fall in diastolic blood pressure.

That trial's metadata is not verified here and the figure is not asserted as fact. A study matching the description appears to exist in the literature from the mid-to-late 2010s, but the authors, journal and exact results are not stated because they could not be confirmed. A topic search is provided below. Naming a paper on inference would be a guess dressed as a citation.

What can be said confidently is how to read the number. "80% higher" is a relative figure, and relative figures conceal their own size. If the control group lost 1.0 kg of fat and the olive-oil group 1.8 kg, that is 80% higher and the absolute difference is 0.8 kg. If the control lost 0.3 kg and the intervention 0.54 kg, that is also 80% higher, and the difference is 240 grams — below what a bathroom scale reliably detects and within normal day-to-day variation in body water. The relative figure is identical; the practical meaning is not.

Three questions convert one into the other, and none can be answered from the relative number alone: what did the control group do; over how long; and was the oil added or substituted, with energy matched. None of this means the trial is bad or the result untrue — it means the headline number alone does not tell you whether the effect is meaningful. Whenever a percentage improvement is quoted without the two numbers it was computed from, those are the missing facts to find. The site's page on realistic expectations makes the same argument across the wider weight-loss literature.

Back to Table of Contents

The EFSA Polyphenol Threshold

There is a verifiable, label-relevant anchor for olive-oil quality that the video never mentions, despite spending several minutes on the problem it solves. In 2011 the European Food Safety Authority approved a health claim for olive oil polyphenols. To carry it, an oil must deliver at least 5 mg of hydroxytyrosol and its derivatives per 20 g of oil — about 250 mg/kg — demonstrated by laboratory assay, with the label stating that the effect requires a daily intake of 20 g, roughly a tablespoon and a half. The chemistry and the real-world range of polyphenol concentrations belong to the polyphenols and oleocanthal page and are not repeated here.

What matters is what kind of instrument this claim is, because regulatory approvals are routinely quoted as though they were trial results.

So the correct use of the claim is as an answer to the video's own question, "how do I know this bottle has anything in it?" — not as evidence that the bottle will do what the video says. It is a purity standard being read as an efficacy standard. One practical limit: it is a European instrument, uncommon in the United States where the FDA does not adopt EFSA claims; where unavailable, a published polyphenol assay figure plus a harvest date is the working substitute.

One correction belongs here too. The video states that "close to 90%" of supermarket olive oil "probably does nothing." The frequently cited laboratory finding is that 73% of imported supermarket samples tested by the UC Davis Olive Center failed at least one International Olive Council standard. Two distortions: the percentage inflated, and "failed at least one grade standard" converted into "does nothing." An oil can fail a sensory or acidity standard and still be a serviceable monounsaturated fat with some polyphenol content. The real finding is serious enough without amplification.

Back to Table of Contents

Who Is Telling You This, and What Is Being Sold

A reader deserves to know where a recommendation originates. This is stated factually and is not an argument against the pharmacology.

The source video's final minutes are a sales pitch. The presenter states that he has partnered with a subscription olive-oil club, that he uses it personally and recommends it to his audience, and directs viewers to a link and QR code for an exclusive offer — buy two bottles, receive a third free, with a money-back guarantee and a note that batches are limited. He also promotes a branded ten-day challenge, his podcast, and a follow-up video on a different "natural Ozempic alternative."

None of that makes the pharmacology wrong. Pancreatic lipase still produces 2-monoacylglycerol; GPR119 still responds to it; PPAR-alpha knockouts still fail to respond to oleoylethanolamide. An argument is not refuted by the interests of the person making it, and treating a commercial relationship as proof of falsehood is its own error.

What the relationship should do is point scepticism at the parts of the argument that create demand for the product, which are structurally distinct from the mechanism: the claim that supermarket extra-virgin oil is largely worthless, which makes an ordinary bottle inadequate; the "close to 90%" figure, higher than the laboratory finding it derives from; the home taste test as a grading method — pungency does track phenolic content, but it is an ordinal sensory impression, not an assay, and exactly the kind of test that confirms whatever the person doing it expects; and harvest date as "the truth," directionally correct and also the specific feature the recommended product is described as having.

Notice the shape: the mechanism section creates a desire, the quality section makes your existing bottle fail, and the product resolves a problem the video created three minutes earlier. That pattern is worth recognising independently of whether any individual claim within it is true. Here several of them are.

Two items to note plainly. The video opens with a community testimonial figure — over a million pounds of fat loss reported by the presenter's audience over eighteen years — which is an uncontrolled, self-reported, unverifiable aggregate carrying no evidential weight in either direction. And the video does say, correctly and unprompted, that none of it is medical advice and that nobody should stop a prescribed medication. That deserves credit; many videos in this genre do not say it.

Back to Table of Contents

What a Trial That Settled This Would Look Like

The practical question — does adding olive oil to an unchanged diet help, hurt, or do nothing to body composition? — is answerable with existing methods. Nobody has answered it. The design would be three arms, randomised, twelve to twenty-four weeks:

  1. Addition arm. Usual diet plus three tablespoons per day of high-polyphenol extra-virgin olive oil, added on top — deliberately creating a surplus of roughly 360 kcal/day if uncompensated. This is the protocol as popularly recommended, and the arm nobody runs.
  2. Substitution arm. The same three tablespoons replacing an isocaloric quantity of habitual fat — what almost all existing evidence actually tested.
  3. Polyphenol-stripped control. The same quantity of refined olive oil, near-identical fatty-acid profile with polyphenols removed, which separates the oleic-acid mechanism from the polyphenol mechanism. The EUROLIVE study used exactly this comparison to isolate polyphenol effects on blood lipids.

Endpoints, in order of importance: fat mass by DXA rather than scale weight, since weight over twelve weeks is dominated by water and glycogen; waist circumference as the cheap correlate of visceral fat; ad libitum energy intake at a laboratory test meal, which measures compensation directly — the central unknown; free-living energy intake by weighed record or doubly labelled water, the only way to know whether compensation happened outside the lab; postprandial active GLP-1, CCK and PYY area-under-curve at baseline and endpoint, to confirm the mechanism is engaged and test whether it attenuates with chronic exposure — the problem the GPR119 drug programmes ran into; and validated appetite visual-analogue scales.

The hard part. Blinding is the real obstacle. The pungency that signals high polyphenol content is a conscious sensory experience — it is the entire basis of the throat-burn test — so a participant given high-polyphenol oil and one given refined oil can tell instantly. The very property being tested defeats the blind for any subjective endpoint. Workarounds exist: opaque capsules, blending into strongly flavoured foods, or relying on objective endpoints. This is a genuine methodological difficulty rather than mere neglect, and it partly explains why the trial has not been run. But "nobody bothered" and "this is genuinely hard to test" are different, and the second is not an excuse for the first — the addition-versus-substitution question could be answered with objective endpoints and no blinding at all.

Back to Table of Contents

Evidence Ledger

The strongest tiers sit at the mechanism end and the weakest at the outcome end — the opposite of how the claim is usually presented.

Established, in humans

Established, but in animals or cells

Reported but unverified

Absent — never adequately tested

Negative — tested and failed

Checked and clear

Several usual failure modes are absent, and saying so is as much a part of accuracy as flagging the ones present. No species substitution in the core human trial; no route substitution (oral, with food, as recommended); no preparation substitution (ordinary olive oil on a vegetable, not an extract or isolate). The substitution that is present is endpoint substitution — a postprandial hormone result standing in for a fat-loss result — plus species substitution in the OEA arm, where the decisive experiment is a mouse.

Back to Table of Contents

What Is Actually Reasonable to Do

  1. Use olive oil as a replacement, not an addition. The highest-value change, what the trials tested, and it costs nothing in energy.
  2. If you add it on top, count it. Four to six tablespoons a day is 500 to 700 kcal, and whether appetite compensates is genuinely unknown. Treat it as an experiment on yourself over eight to twelve weeks rather than assuming the mechanism will handle it.
  3. Take it with food. This part of the video's protocol is mechanistically correct: 2-OG and OEA come from digesting the fat, and satiety signalling is only useful if it coincides with the meal it is meant to limit.
  4. Buy on verifiable markers — harvest date, a published polyphenol figure, dark glass, the EFSA claim where available. The extra virgin quality page covers this, and no subscription club is required.
  5. Do not expect a drug-like effect or substitute this for prescribed treatment. If you take or are considering a GLP-1 receptor agonist, that decision belongs with your prescriber.
  6. Reduce fat per meal with gastroparesis; be cautious with large fat loads if you have gallstones. The mechanism producing the fullness is the mechanism producing the problem.
  7. Judge olive oil on its strongest evidence, not its most exciting. Heart health is a much better reason to eat it than GLP-1.

Back to Table of Contents

Key Research Papers

Links are PubMed topic searches rather than fixed identifiers, so they retrieve current literature and no citation here rests on unconfirmed metadata. Where a study is described from a secondary source, the entry says so.

  1. Mandøe MJ and colleagues, on the 2-monoacylglycerol moiety of dietary fat and fat-induced GLP-1 release in humans — American Journal of Clinical Nutrition, around 2015. Design described from a secondary source; verify before citing. — PubMed: 2-monoacylglycerol and GLP-1 in humans
  2. 2-oleoylglycerol as a GPR119 agonist and incretin secretagogue — PubMed: 2-oleoylglycerol and GPR119
  3. GPR119 as a therapeutic target in type 2 diabetes, the clinical fate of synthetic agonists, and receptor desensitisation — PubMed: GPR119 agonists in clinical development
  4. Fu J and colleagues, on oleoylethanolamide regulating feeding and body weight through the nuclear receptor PPAR-alpha — Nature, around 2003. The knockout experiment described above. — PubMed: OEA and PPAR-alpha
  5. Oleoylethanolamide, vagal afferent signalling and satiety — PubMed: OEA and vagal satiety signalling
  6. Oleoylethanolamide and adipocyte lipolysis — cell and tissue work distinct from the Nature feeding study; primary source not identified here. — PubMed: OEA and lipolysis
  7. Dietary oleic acid content, postprandial OEA response and subsequent energy intake in humans — reported by the source video as appearing in Food & Function in 2015; metadata unverified. — PubMed: dietary oleic acid and human OEA response
  8. PPAR-alpha knockout phenotype — impaired fasting hepatic fatty-acid oxidation and ketogenesis — PubMed: PPAR-alpha null phenotype
  9. Adipose triglyceride lipase and hormone-sensitive lipase — the actual effectors of adipocyte lipolysis — PubMed: lipolysis effectors
  10. Native GLP-1 half-life and degradation by dipeptidyl peptidase-4 — PubMed: GLP-1 half-life and DPP-4
  11. DPP-4 inhibitors — glycaemic efficacy and weight neutrality — PubMed: DPP-4 inhibitors and body weight
  12. Semaglutide pharmacokinetics (albumin binding, half-life, weekly dosing) and the STEP weight-loss trials — PubMed: semaglutide pharmacokinetics and weight loss
  13. Blunted incretin and GLP-1 responses in obesity and type 2 diabetes — PubMed: blunted incretin response
  14. Cholecystokinin, peptide YY and the regulation of gastric emptying and satiety by dietary fat — PubMed: CCK, PYY and fat-induced satiety
  15. Olive oil versus other dietary fats and body weight — meta-analyses of randomised trials, including the 2017 analysis cited by the source video — PubMed: olive oil and body weight meta-analyses
  16. Extra-virgin olive oil, body composition and blood pressure in women with excess body fat — the trial behind the "80% higher fat loss" figure; metadata unverified. — PubMed: EVOO, body composition and blood pressure in women
  17. High-phenolic olive oil in metabolic syndrome — liver enzymes, inflammatory markers and hepatic steatosis — PubMed: high-phenolic olive oil in metabolic syndrome
  18. Pancreatic lipase regiospecificity, sn-2 oleic acid distribution in olive oil, and the fate of 2-monoacylglycerol during digestion — PubMed: lipase specificity and sn-2 distribution
  19. Enteroendocrine L-cell distribution along the gut and the proximal-distal loop — PubMed: L-cell distribution and GLP-1 secretion
  20. EFSA scientific opinion on olive oil polyphenols and protection of blood lipids from oxidative stress — PubMed: EFSA olive oil polyphenol claim
  21. Energy compensation and the limits of the 3,500 kcal per pound rule — dynamic models of human body-weight change — PubMed: dynamic body-weight models

Back to Table of Contents

Connections

Back to Table of Contents